Effect of brensocatib treatment on active NE levels in WBCs
±
The total number of reportable NE activities from the blood samples at baseline and over the course of the trial was 256 for placebo, 239 for 10 mg brensocatib, and 299 for 25 mg brensocatib. The effect of treatment on NE activity in WBCs was also evaluated. Active NE levels in WBC extracts were reduced by brensocatib by week 4 in a dose-dependent manner, which was maintained over the 24 weeks, with a recovery to baseline levels 4 weeks after the end of treatment (Fig. NE activity in WBCs on study. Change from baseline is presented as mean (± SEM) for NE. * P < 0.05 vs placebo at the same timepoint